New drugs and generics will enter the arthritis treatment market with a full of medications that reduced the heartburn side effect

It is known that the nonsteroidal anti-inflammatory drug (NSAIDs) market is getting hotter as many arthritis treatments that reduced gastrointestinal side effects enter.

As the Pfizer’s COX-2 inhibitor ‘Celebrex’ is leading the market, new drugs and generics is about to challenge it.

Complexes combining NSAIDs and proton pump inhibitors (PPI) have not reached expectations on them when they we...